Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 8:17:441-455.
doi: 10.1016/j.ibneur.2024.11.004. eCollection 2024 Dec.

Exploring the potential of probiotics in Alzheimer's disease and gut dysbiosis

Sowmiya S  1 , Dhivya L S  2 , Praveen Rajendran  1 , Harikrishnan N  3 , Ankul Singh S  1
Affiliations
Review

Exploring the potential of probiotics in Alzheimer's disease and gut dysbiosis

Sowmiya S et al. IBRO Neurosci Rep. .

Abstract

Alzheimer's disease is a fatal neurodegenerative disorder that causes memory loss and cognitive decline in older people. There is increasing evidence suggesting that gut microbiota alteration is a cause of Alzheimer's disease pathogenesis. This review explores the link between gut dysbiosis and the development of Alzheimer's disease contributing to neuroinflammation, amyloid β accumulation, and cognitive decline. We examine the recent studies that illustrate the gut-brain axis (GBA) as a bidirectional communication between the gut and brain and how its alteration can influence neurological health. Furthermore, we discuss the potential of probiotic supplementation as a management approach to restore gut microbiota balance, and ultimately improve cognitive function in AD patients. Based on current research findings, this review aims to provide insights into the promising role of probiotics in Alzheimer's disease management and the need for further investigation into microbiota-targeted interventions.

Keywords: Alzheimer’s disease; Gut microbiota; Gut-brain axis; Neuroinflammation; Probiotic supplementation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
IMMUNE PATHWAY, VAGUS NERVE PATHWAY, HPA AXIS.
Fig. 2
Fig. 2
Microbiota dysbiosis in Alzheimer’s disease.
See this image and copyright information in PMC

References

    1. Aczel D., Gyorgy B., Bakonyi P., Bukhari R., Pinho R., Boldogh I., Yaodong G., Radak Z. The systemic effects of exercise on the systemic effects of Alzheimer’s disease. Antioxidants. 2022 doi: 10.3390/ANTIOX11051028. aging-12-103900, n.d. - DOI - PMC - PubMed
    1. Akbari E., Asemi Z., Kakhaki R.D., Bahmani F., Kouchaki E., Tamtaji O.R., Hamidi G.A., Salami M. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front Aging Neurosci. 2016;8 doi: 10.3389/fnagi.2016.00256. - DOI - PMC - PubMed
    1. Ale E.C., Binetti A.G. Role of probiotics, prebiotics, and synbiotics in the elderly: insights into their applications. Front Microbiol. 2021 doi: 10.3389/fmicb.2021.631254. - DOI - PMC - PubMed
    1. Aleman R.S., Moncada M., Aryana K.J. Leaky gut and the ingredients that help treat it: a review. Molecules. 2023 doi: 10.3390/molecules28020619. - DOI - PMC - PubMed
    1. Anwar H., Iftikhar A., Muzaffar H., Almatroudi A., Allemailem K.S., Navaid S., Saleem S., Khurshid M. Biodiversity of gut microbiota: impact of various host and environmental factors. Biomed. Res Int. 2021;2021 doi: 10.1155/2021/5575245. - DOI - PMC - PubMed

LinkOut - more resources